RA Capital Management, L.P. 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-15 5:05 pm Sale | 2024-11-13 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA Capital Management, L.P. | 5,098,211 11.000% | -103,934 (-2.00%) | Filing |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA Capital Management, L.P. | 5,202,145 9.990% | 1,038,934 (+24.96%) | Filing |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA Capital Management, L.P. | 4,163,211 9.700% | 1,373,490 (+49.23%) | Filing |
| 2023-06-05 4:31 pm Purchase | 2023-05-25 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA Capital Management, L.P. | 2,789,721 6.700% | 2,789,721 (New Position) | Filing |